Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes. The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.